Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5181 - PNU-74654 enhances the antiproliferative effects of 5-FU in breast cancer and antagonizes thrombin induced cell growth via the Wnt Pathway

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Immunology

Tumour Site

Breast Cancer

Presenters

Soodabeh Shahid Sales

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

S. Shahid Sales1, A. Avan2, F. Rahmani3, S.M. Hassanian2, M. Hashemzehi2, F. Amerizadeh2, G. A. Ferns4, M. Khazaei5

Author affiliations

  • 1 Clinical Oncology, Cancer Research Center, Mashhad University of Medical Sciences, 9176613775 - Mashhad/IR
  • 2 Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, 9176613775 - Mashhad/IR
  • 3 Department Of Medical Biochemistry, Faculty Of Medicine, Mashhad University Of Medical Sciences, Mashhad, Iran., Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., 9176613775 - mashhad/IR
  • 4 Division Of Medical Education, Brighton & Sussex Medical School, Falmer/GB
  • 5 Department Of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, 9176613775 - mashhad/IR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5181

Background

The Wnt/beta-catenin pathway is one of the main pathways that are dysregulated in several malignancies, including breast cancer, and may therefore be a potential therapeutic target. We have investigated the anticancer activity of PNU-74654 in breast cancer, as a Wnt/ β-catenin inhibitor, either alone or in combination with 5-FU in vitro and in vivo.

Methods

Cell viability was assessed in 2 and 3-dimensional (D) cell culture models. The ability of PNU-74654 to inhibit the chemotaxis of cells was investigated using an in vitro migration assay, and the expression of several candidate genes involved in the cell cycle, migration, as well as the markers of Wnt/b-catenin pathway were investigated by qRT-PCR and/or Western blotting as well as cell cycle analysis by flow cytometry. The effect of PNU-74654 on oxidative balance was evaluated by determining the malondialdehyde (MDA) and concentration of total thiols (T-SH), and the activity of catalase (CAT) and superoxide dismutase (SOD). We reconstructed a Boolean network in order to understand dynamic behavior of genes, while the robustness of this model was assessed by Hamming distance.

Results

PNU-74654 suppressed cell growth at an IC50 of 122±0.4 umol/L and synergistically enhanced the antiproliferative activity of gemcitabine by modulating the Wnt pathway. The 3-D cell culture model showed that PNU-74654 caused tumor shrinkage. It reduced the migration of MCF-7 cells (by an 18% reduction in invasive behavior) after treatment with PNU-74654 through perturbation of E-cadherin and MMP3/9. PNU-74654/5-FU combination enhanced the percentages of cells in S-phase, and significantly increased apoptosis. Moreover, our data showed that this agent was able to inhibit the growth of tumor in a xenograft model, although this effect was more pronounced in the animals treated with PNU-74654 plus 5-FU.

Conclusions

The antitumor activity of PNU-74654 were shown in breast cancer.

Clinical trial identification

Legal entity responsible for the study

Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

Mashhad University of Medical Sciences, Mashhad, Iran.

Editorial Acknowledgement

Mashhad University of Medical Sciences, Mashhad, Iran

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.